SCHEDULE: Millennium Entities Disclose 9% Stake in Quoin Pharma

Millennium Management and affiliated entities have reported a 9.0% beneficial ownership stake in Quoin Pharmaceuticals Ltd. through a Schedule 13G filing.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander collectively reported beneficial ownership of 1,901,585 Ordinary Shares of Quoin Pharmaceuticals Ltd.
• This represents 9.0% of Quoin Pharmaceuticals Ltd.'s Ordinary Shares outstanding.
• All reporting persons have shared voting and dispositive power over the 1,901,585 shares.
• The percentage was calculated based on 21,116,150 Ordinary Shares outstanding as of October 14, 2025, which includes shares from a recent private placement.
• The securities were not acquired for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant passive stake by a reputable institutional investor like Millennium Management is generally viewed positively, indicating confidence in the company's value, even if it's not an active endorsement of management or strategy.

Positives

• Significant institutional investment from Millennium Management and its affiliates, potentially signaling confidence in Quoin Pharmaceuticals Ltd.'s long-term prospects.
• The filing indicates a passive investment, not intended to influence control, which can be viewed positively by existing management and shareholders.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Quoin Pharmaceuticals Ltd. or the reporting entities regarding the issuer's future performance.

Management Comments

• The securities referred to were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing reflects a significant institutional investor taking a passive stake in Quoin Pharmaceuticals Ltd. Such filings are common in the biotechnology and pharmaceutical sectors, where specialized funds often invest in companies with promising pipelines or market positions. A 9% stake from a prominent firm like Millennium Management can draw attention to Quoin Pharmaceuticals within the investment community, potentially increasing visibility and investor interest.

Comparison to Industry Standards

• A 9.0% passive stake by a major hedge fund like Millennium Management is a substantial position, often seen as a vote of confidence in a company's long-term prospects, particularly in the biotech sector where early-stage investments can be volatile.
• Compared to other institutional filings, a Schedule 13G indicates a passive investment intent, differentiating it from an activist stake (often filed as a 13D) where the investor seeks to influence management or corporate strategy.

Stakeholder Impact

• Shareholders: May view the institutional investment as a positive signal, potentially increasing investor confidence and liquidity.
• Investment Community: The filing could attract more attention to Quoin Pharmaceuticals Ltd. from other institutional investors and analysts.

Next Steps

• Quoin Pharmaceuticals Ltd. will continue its operations and disclosures as per SEC regulations.
• Millennium Management and its affiliates will continue to monitor their investment in Quoin Pharmaceuticals Ltd.

Key Dates

Recommendation

The filing indicates a significant passive stake by a major institutional investor, which is generally a positive signal. However, it does not provide new operational or financial performance data for Quoin Pharmaceuticals Ltd. to warrant a 'buy' recommendation. It primarily confirms a substantial ownership position, suggesting existing investors might 'hold' based on this vote of confidence, while new investors would need to conduct further due diligence beyond this ownership disclosure.

Keywords

Quoin Pharmaceuticals, Millennium Management, Integrated Core Strategies, Israel A. Englander, Schedule 13G, Beneficial Ownership, Ordinary Shares, Institutional Investment, Equity Stake